



Post Authorisation Assessments

Ketavet 100 mg/ml Solution for Injection for Dogs, Cats and Horses Vm 42058/5101

04 September 2025	Addition of a site where batch control or testing of the active substance takes place. Addition of a site where batch control or testing of the active substance takes place.
04 September 2025	Addition of a specification parameter with its corresponding test method to the active substance specification as a result of a safety or quality issue. Update to a Ph. Eur. CEP for an already authorised manufacturer of the active substance.
July 2024	Minor change to an approved test procedure for the finished product.
31 July 2024	Change in any part of the primary packaging material not in contact with the finished product formulation.
17 July 2024	Minor change to an approved test procedure for the finished product.
07 March 2024	Submission of an updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: – active substance.
03 August 2023	One-off alignment of the product information with version 1 of the national QRD template.
05 May 2020	Increase in the shelf-life of the finished product as packaged for sale, from 2 years to 3 years.
03 February 2020	Renewal - UK as CMS
12 November 2019	Change in the address of the marketing authorisation holder from Zoetis UK Limited 5th Floor, 6 St. Andrew Street London EC4A 3AE to Zoetis UK Limited 1st Floor, Birchwood Building Springfield Drive Leatherhead Surrey KT22 7LP.
25 September 2018	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
17 April 2018	Change in RMS from UK to ES.
29 December 2016	Change in the address of the marketing authorisation holder in France, Czech Republic & Slovakia.
05 April 2016	Changes to the manufacturing process.
05 May 2015	Change to the QPPV contact details.